BRAF and colorectal carcinoma: Although both KRASG12X mutations and the BRAF V600E mutation are key drivers of cell proliferation and survival in CRC through the activation of the MAPK (RAS/RAF/MEK/ERK) signaling pathway, they are associated with distinct clinical outcomes [47].